Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538025 | 0.84 | MAPT (0.78) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL1420033 | 0.83 | TP53 (0.81) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL155002 | 0.83 | MAPT (1.00) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL5543729 | 0.81 | MAPT (0.72) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL5537492 | 0.80 | MAPT (0.76) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL9642061 | 0.79 | MAPT (0.84) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL2621291 | 0.79 | MAPT (0.70) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL2792617 | 0.79 | NPC1 (0.70) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL622536 | 0.79 | NPC1 (0.70) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL1786789 | 0.79 | LOXL2 (0.72) | NPC1RAB9AMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759532-A | A kind of the ethyl 9 oxime derivate of benzoxazole 2, its preparation method and application | 苏州大学 | 2018-03-06 | — | — | CN | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| CN-101421257-A | Agents that disrupt cellular replication and their use in inhibiting pathological conditions | EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) | 2009-04-29 | — | — | CN | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| CN-111511465-B | Method for producing organic silicon dioxide material and use thereof | 埃克森美孚科技工程公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11325111-B2 | Catalysts and methods of making the same | EXXONMOBIL RESEARCH & ENGINEERING COMPANY (US) | 2022-05-10 | — | — | US | disclosed |
| CN-109311001-B | Organosilica polymer catalyst and method for producing same | 埃克森美孚研究工程公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11111352-B2 | Methods of producing organosilica materials and uses thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2021-09-07 | — | — | US | disclosed |
| CN-107001945-B | Aromatic hydrogenation catalyst and use thereof | 埃克森美孚研究工程公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-1996040141-A1 | 4,5-BRIDGED QUINOXALINEDIONES AND QUINOLONES AND THE USE THEREOF AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
| US-4576753-A | MICROBIOCIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| US-4472309-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4304718-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4264498-A | REACTED WITH AN ACID, ITS ACID HALIDE, OR ANHYDRIDE IN THE PRESENCE OF BORON TRIHALIDE AND AN ORGANIC BASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-28 | — | — | US | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | NPC1 2406/4885RAB9A 1696/4885MAPT 2437/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | NPC1 2406/4885RAB9A 1696/4885MAPT 2437/4885 |
| US-11325111-B2 | Catalysts and methods of making the same | CAT, STOM, SOD1 | NPC1 1201/4885RAB9A 2386/4885MAPT 2655/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | NPC1 2468/4885RAB9A 1619/4885MAPT 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.